Drugs / Concentrated Bone Marrow Aspirate Injection
Concentrated Bone Marrow Aspirate Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06311513 | Jan 2024 → Dec 2027 expected | osteoarthritis, knee | Hospital for Special Surgery, New York | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Concentrated Bone Marrow Aspirate Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06311513 ↗ |
| Modality | Cell therapy | “Concentrated bone marrow aspirate (cBMA) is a regenerative medicine therapy that contains soluble factors and connective tissue progenitor cells” NCT06311513 ↗ |
| Route | Other | “an injection of the resulting concentrated product (cBMA) will be administered in the operative knee” NCT06311513 ↗ |